Compare Global X FTSE Southeast Asia ETF (ASEA) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Viatris Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Viatris Inc trades at $16.36 (market cap $18.94B). The key difference: Viatris Inc pays a 2.95% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $17.39 |
52-Week Low | $16.31 | $8.74 |
Market Cap | — | $18.94B |
Enterprise Value | — | $31.15B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.
The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
